CardioGenics Holdings Inc. (CGNH)

[DADDY FAT SAXX]

The reverse split probably did not help things either. IMO. 1 for 10 RS not a big deal but penny players see RS and run the other direction. That stock was valued much higher back in July and has actually dropped about .20. The Merck deal is a nice bit of news but obviously it did not move the stock all that much. For a small float stock news like the Merck deal should have shot this up much higher. On May 20th the company hired an IR firm and I wonder if they gave the IR firm shares or payment?

Also it is not the Merck that everyone knows it is this Merck

Merck Chimie SAS is mainly a sale & marketing organization, being part of the chemical branch of the Merck Group, in charge of French and Maghreb territory.

The French Division of Merck

http://www.bing.com/search?q=Merck+Chimie+S.A.S.&src=IE-SearchBox&Form=IE8SRC

So it is a very limited segment of Merck.

If you became interested in this stock 2 months ago you must have bought it when it was around .50 to .60 or higher.

If the deal with thses guys was for MERCK Global that would be BIG NEWS but these penny companies get deals in Europe all the time.

The board is dead too so looks like very little interest here. Maybe the volume jumps are from the Europeans buying in but even then the pps is not jumping all that much IMO.

Oh and where is the IBOX. There is absolutely no information in the IBOX about this stock. I mean if I did not look up the company myself I would have no idea what the company does. If you want board traffic you have to let people know what they might be investing in. IMO.

GLTY

[StormyStocks]

I see and yes, I know how IHub posters can be at times. Many are very nice. I believe a lot of what happens on boards are a matter of tolerance from the moderators. While its healthy to have active debates, bashing is commonplace. Perhaps people will come back to IHub when the stock begins doing better.

[pontiyak]

Lady... if you check the posting dates, you will see not too many people post here. most inhabit raging bull. Sadly I believe it is due to IHubs reputation as a basher/HedgeHog© controlled chat site. But some of us do stop in from time to time. I too like the news and the increase in volume, but I suspect CGNH still has a ways to go before they shed the monkeys that may be on their backs.

IMHO

yak

[StormyStocks]

A little background about what brought me to this stock. I am a nurse who specialty is cardiology. Looking for investment opportunities, I happened upon CGNH about two months ago and have been keeping an eye on it ever since.

Now that CGNH has sign with Merck, this stock is set to soar! Very low float considering the scope of promise here. The volume is going up higher than it has in the past two months. Time to get this off of the ground and watch it grow. IMHO, this is a perfect stock for longs, but also suited for those that prefer to play.

[StormyStocks]

Today is the largest volume CGNH has experienced since JUNE 2010. It has come to life in a fabulous way! The float is a mere 27 million. This is unheard of in our world. Magnificently wonderful things to come for this company and its stock. Best of luck to everyone!

[StormyStocks]

Okay, I am back and nobody posting about CGNH? Now, I am sure everyone knows that the symbol recently changed, right? It used to be CGNHD, but dropped the "D" about a week ago.

If you follow Google finance, at least, it will render an invalid symbol. Guess CGNH hasn't caught up with Google yet.

[StormyStocks]

Merck Set to Distribute CardioGenics Beads for Central Lab Diagnostic Analyzers

Read the news! This is HUGE people.

[StormyStocks]

I am SHOCKED this place is not just buzzing with activity. New news just out today. Excellent teaming with Merck, an outstanding multibillion dollar company. What more could we ask for, really? CGNH jumped big time today, over 32%. Hello?

[DumpOnUrPump]

Seems to be decent news here today. The recent 1:10 R/S stinks

[zino]

investors were paying .10 cents options...

[zino]

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following shares of our Common Stock were issued to a current stockholder of the Company upon exercise of a warrant:

Date of Exercise Exercise Price/Share Shares Exercised Aggregate Exercise Amount
February 1, 2010 $ 0.047 750,000 $ 35,250



On February 10, 2010, a current stockholder of the Company purchased 500,000 shares of our Common Stock for an aggregate purchase price of $50,000.[/b]
On February 28, 2010, a current stockholder of the Company purchased 270,000 shares of our Common Stock for an aggregate purchase price of $27,000

[pontiyak]

Nice press.. :)

[thepennyhopefuls]

http://www.thefirstreporter.com/press-releases/hot-small-otc-pharma-to-watch/

Nice small press on this. Gonna take a position today.

[pontiyak]

MISSISSAUGA, Ontario, May 28

MISSISSAUGA, Ontario, May 28 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care? Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, is spotlighted in the May issue of Medical Tourism Magazine in an article written by CardioGenics founder and CEO Yahia Gawad, MD.

In the article, titled "The In Vitro Diagnostics Market and the Fight Against Heart Problems," Dr. Gawad notes that reducing the time required to diagnose a cardiac event is a key factor in saving the lives of patients with acute heart problems. ?Recent significant growth in the IVD market promises a new generation of technological advances -- such as CardioGenics' QL Care Analyzer -- that will improve options for rapid Point-of-Care (POC) testing abroad as well as in the U.S.

"A significant fraction of patients who travel overseas for surgery are doing so because of heart problems," Dr. Gawad writes in the article. ?"In fact, heart surgery is one of the top five types of surgeries that motivate travel abroad. ?But this fact begs the question: ?What happens if one experiences an acute cardiac episode overseas before one has had the chance to undergo one's scheduled procedure? ?The fact is that the amount of time it takes to diagnose a heart attack is currently much longer in foreign countries in comparison to North America." ?

Dr Gawad goes on to write that new technology is being developed that may finally level this particular playing field. ?Specifically, he highlights the rapid growth in the POC test market, encompassing diagnostic tests that can be conducted at or near the site of patient care. ?A Troponin I (TNI) test, a Plasminogen Activator Inhibitor type-1 (PAI-1) test, a heart failure risk stratification test, and a heart failure genomics risk test are all in development for the benefit of cardiac care patients.

"If and when POC immunoanalyzers are sold abroad...the effect on medical tourism will likely be significant," writes Gawad in the article. ?"No longer will heart patients need to fret about lack of timely diagnosis when suffering a possible cardiac episode prior to undergoing their scheduled procedure in a foreign healthcare facility.... The time required for accurate diagnosis will be rapidly reduced and roughly equalized everywhere."

To read the entire article online, please visit http://www.medicaltourismmag.com/detail.php?Req=366&issue=17.

About Medical Tourism Magazine

Medical Tourism Magazine is published by the Medical Tourism Association?, the first international non-profit association made up of the top international hospitals, healthcare providers, medical travel facilitators, insurance companies, and other affiliated companies and members with the common goal of promoting the highest level of quality of healthcare to patients in a global environment. The association promotes the interests of its healthcare provider and medical tourism facilitators members. The Medical Tourism Association ? has three tenets: Transparency, Communication and Education. For more information, please visit www.medicaltourismmag.com.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops its Point-Of-Care analyzer and products targeting the immunoassay segment of the IVD market. It has developed the QL Care? Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating magnetic beads (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement -Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.

[pontiyak]

MISSISSAUGA, Ontario, May 27 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH), developer of the ultra-sensitive QL Care? Point-Of-Care analyzer and products for the immunoassay segment of the In-Vitro Diagnostics (IVD) market, announced today a further update regarding the status of its agreement with Merck Chimie S.A.S. ("Merck Chimie"), one of the largest manufacturers and distributors of magnetic beads for the diagnostics market.

This week the Company received from Merck Chimie a second shipment of CardioGenics' proprietary silver-plated magnetic beads (the "CardioGenics Beads") encapsulated by Merck Chimie and will begin bench testing those beads this week. This shipment includes 10 different sets of the CardioGenics Beads, encapsulated by several processes by Merck Chimie. The testing process determines the chemical stability and biological compatibility of the encapsulated beads. ?After completing the testing of the encapsulated beads of this shipment, the Company will review the testing results with Merck Chimie. If the parties determine that no further technical adjustments are necessary to the encapsulation process, the Company and Merck Chimie intend to finalize commercialization plans by which Merck Chimie would increase production of the final encapsulated CardioGenics Beads to commercial size lots for distribution to Merck Chimie's customers.

In the Company's prior announcement on this matter, the Company noted that, after analyzing the first shipment of the CardioGenics Beads that were encapsulated by Merck Chimie, both parties agreed that Merck Chimie would undertake certain technical adjustments to the encapsulation process to optimize performance of the CardioGenics Beads during commercialization and then deliver to the Company a second shipment of encapsulated CardioGenics Beads for further testing by the Company.

About Merck Chimie S.A.S.

Merck Chimie S.A.S. is part of the Chemicals business sector of the Merck Group. The Merck Group is a global pharmaceutical and chemical enterprise operating in?64?countries with total revenues of approximately euro 7.7 billion (2009). The Pharmaceuticals business sector comprises innovative prescription drugs as well as over-the-counter products. The Chemicals business sector offers specialty products for the electronics, printing, coatings, cosmetics, pharmaceutical and biotech industries. Merck Chimie S.A.S. includes R&D and production activities for Estapor Microspheres, which are sold all over the world, primarily to the diagnostics market.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops its Point-Of-Care analyzer and products targeting the immunoassay segment of the IVD market. It has developed the QL Care? Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating magnetic beads (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.

[pontiyak]

this board is pretty quiet. most hang out on the RB board.

yak

[thepennyhopefuls]

How is there no activity on this board?

Saw 80% today on awesome news. More to come for sure. Let's start the chatter.

twitter.com/ActualGains is covering this stock pretty extensively.

[pontiyak]

CardioGenics to be Spotlighted in Three Publications During Month of April
CEO Yahia Gawad Discusses Company Products and Goals in Today's Medical Developments, Medical Design Technology and The Wall Street Transcript
PR Newswire

MISSISSAUGA, Ontario, April 22

MISSISSAUGA, Ontario, April 22 /PRNewswire-FirstCall/ -- CardioGenics Inc. (OTC Bulletin Board: CGNH), a developer of technology and products targeting the immunoassay segment of the IVD testing market, will be spotlighted in three publications during the month of April: Today's Medical Developments, Medical Design Technology and The Wall Street Transcript.

In the April 2010 print and online editions of Today's Medical Developments, senior editor Elizabeth Engler Modic contributes an article titled "Going from Hours Down to Minutes Saves Lives." In the article, Modic describes the QL Care analyzer, a sensitive and accurate point-of-care (POC) analyzer, which was conceived and developed by a team led by CardioGenics founder and CEO Yahia Gawad, Ph.D. Gawad comments on the market need for a new POC analyzer that can reduce the time required to diagnose a cardiac event and other conditions, outlines the prototyping and testing phases, describes its advantages over existing products, and summarizes future steps leading up to its commercial release. ? ?

In the April 2010 print and online editions of Medical Design Technology, Dr. Gawad contributes an article titled "The QL Care Analyzer: A Leap Forward in POC Diagnostics." In the article, Gawad delves into the physical characteristics and technical operation of the QL Care analyzer. For example, he describes the device's use of patent-protected disposable test cartridges and its use of chemiluminescence to derive test results. The analyzer's memory processor, touch LCD screen, and internal printer are among the additional features he describes.

In a Q&A posted on The Wall Street Transcript website on April 5, 2010, Dr. Gawad provides a brief history of CardioGenics, describes why he chose to enter the In Vitro Diagnostics market, and provides additional details on the status of the QL Care analyzer. He highlights some of the challenges of securing the medical community's acceptance of new technology and of doing business during a time when US healthcare options are being dramatically overhauled. ? ? ?

Dr. Gawad remarked: "As CardioGenics continues to grow and to prepare its products for market, we welcome media attention that focuses on what we have to offer the healthcare community. We believe our QL Care analyzer and other products offer the possibility of saving many lives, and such exposure allows potential customers to become aware of our technology and how it could serve their patients."

To read the Today's Medical Developments article, please visit: http://www.onlinetmd.com/tmd-0410-test-results-improves-diagnosis.aspx

To read the Medical Design Technology article, please visit: ?

http://e-ditionsbyfry.com/Olive/ODE/MDT/ and click on p. 20 in the Table of Contents

To read an excerpt of The Wall Street Transcript Q&A, please visit:

www.twst.com

About CardioGenics Holdings Inc.

Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.

Safe Harbor Statement

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.

[pontiyak]

CardioGenics ExchangeCo Inc. ("ExchangeCo"). ExchangeCo and WeirFoulds LLP (as "trustee" under that certain Voting and Exchange Trust Agreement dated July 6, 2009 among the Company, ExchangeCo and WeirFoulds LLP) are also parties to these lock-up agreements.

In addition to the above lock-up agreements by the directors, the Company's Chief Financial Officer, James Essex, agreed to lock-up 3,981,830 shares of the Company's common stock beneficially owned by Mr. Essex until September 22, 2011 and five (5) other long-time stockholders of the Company also agreed to lock-up 10,404,000 shares of the Company's common stock, in the aggregate, beneficially owned by those stockholders until September 22, 2011. The Company's Board of Directors (including Dr. Yahia Gawad) and certain executives and other stockholders of the Company have now locked-up 203,144,943 shares of common stock beneficially owned by them for periods ranging from eighteen (18) months to four (4) years.

Pursuant to the terms of the lock-up agreements, the securities that are subject to the lock-up agreements may not be exchanged or sold by such parties prior to September 22, 2011 (the "Restricted Securities"). Notwithstanding the lock-up provisions, the respective directors, executives and stockholders are permitted under the lock-up agreements to (1) pledge the Restricted Securities as collateral in a loan transaction involving them and (2) transfer the Restricted Securities to members of their immediate family, provided such family members agree, in writing, to be bound by the terms of the lock-up agreements.

In addition, in the event of a "Change-in-Control" of the Company during the lock-up period, the lock-up agreements shall terminate and become of no further force and effect immediately upon the effectiveness of such "Change-in-Control." For purposes of the lock-up agreements, "Change-in-Control" means (i) any acquisition of more than 50% of the outstanding capital stock of the Company by any unrelated third party ("Third Party"); (ii) any merger of the Company into any Third Party; or (iii) any acquisition of substantially all of the assets of the Company by any Third Party.

J. Neil Tabatznik, Chairman of the Board of Directors of CardioGenics Holdings Inc., stated, "Recently, our chief executive officer, Dr. Yahia Gawad, agreed to lock-up 150,000,000 shares of the Company's common stock owned by him for an unprecedented of period of four years, in order to send a clear message to our stockholders and potential investors regarding his sentiments about the Company's long-term and short-term prospects. The directors of CardioGenics enthusiastically concur with Dr. Gawad's sentiments and, accordingly, decided to lock-up their common shares for a period of eighteen months to reinforce that message to our stockholders and potential investors."

The Company will also be filing a Current Report on Form 8-K with further details regarding the lock-up agreements.

About CardioGenics Holdings Inc.

Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada (web address at www.cardiogenics.com).

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.

SOURCE CardioGenics Holdings Inc.

[pontiyak]

CardioGenics Announces Retention of Wolfe Axelrod Weinberger Associates LLC to Provide Investor Relations Services for the Company
Ticker Symbol: U:CGNH





MISSISSAUGA, Ontario, Jan. 20 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. , a developer of technology and products targeting the IVD segment of the Point-Of-Care (POC) diagnostic market, has retained Wolfe Axelrod Weinberger Associates LLC to provide investor relations services for the Company. Effective January 18, 2010, all shareholder inquires should be directed to:



Wolfe Axelrod Weinberger Associates LLC
Tel: [phone]
E-Mail: [e-mail]




IRG, which has been handling both the investor relations and public relations functions for the Company will continue to provide public relations services as Wolfe Axelrod Weinberger commences it's investor relations services.


Dr. Yahia Gawad, CEO of CardioGenics, stated, "We are very happy to have Wolfe Axelrod undertaking investor relations for the Company and IRG continuing to provide public relations services. We believe that with Wolfe Axelrod and IRG working in these capacities we have the right combination to quickly enhance awareness of CardioGenics and its products among the financial community and important media outlets."


Robert Shatz, Managing Director of Wolfe Axelrod stated, "Wolfe Axelrod Weinberger Associates is very pleased to be assisting CardioGenics in its plan to expand investor awareness and improve shareholder values. Its newly developed QL Care Analyzer, a proprietary immuno-analyzer diagnostic testing device, brings a new paradigm to the diagnostic testing marketplace initially with specific benefits in cardiovascular diagnostic tests. The new tests offer significant benefits to the patient and, potentially, dramatically lower health care costs by earlier diagnosis and treatment."


About CardioGenics Holdings Inc.


Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.


Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.



CardioGenics Holdings Inc.
CONTACT: Investor Relations: Robert Schatz, Managing Director of Wolfe
Axelrod Weinberger Associates LLC, [phone], or Media Relations:
Mike Graff of The Investor Relations Group, [phone]

[pontiyak]

Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
Ticker Symbol: U:CGNH





MISSISSAUGA, Ontario, Dec. 30 /PRNewswire-FirstCall/ -- Dr. Yahia Gawad, Chief Executive Officer of CardioGenics Holdings Inc. , a developer of technology and products targeting the immunoassay segment of the IVD testing market, was interviewed in MedTech Executive. The article touches on the technical and market environment for developing its QL Care Analyzer device, the FDA approval process, InVitro Diagnostic (IVD) trends, and the investment climate for immunoassay products following CardioGenics' recent business agreement with Merck Chimie, S.A.S. To read the article in full, please visit http://www.devicelink.com/mx/issuesupdate/09/12/gawad.html


In the interview, Dr. Gawad observed, "Cardiologists and emergency room physicians are demanding more than just yes/no answers" when it comes to cardiac testing. He added, "market penetration figures testify that the climate requires more than the existing cardiac test offerings."


CardioGenics' QL Care Analyzer "is the first Point-of-Care (POC) platform to bring chemiluminescence to the POC immunoassay testing market for those seeking quantitative results. Fundamentally, the QLCA is an immunoassay analyzer that is set up to perform one test at a time in whole blood samples. It is not a miniaturized lab analyzer, in the sense that the technology was imported from lab-based machines. The core technology was specifically developed for the QLCA and works in tandem with numerous other technologies inside it," said Dr. Gawad. This distinguishes the QLCA device because other POC platforms "all are either qualitative, giving simple 'yes' or 'no' answers, or they employ fluorescence, which has a low detection limit."


Cardiogenics is seeking FDA approval for the QL Care Analyzer and three additional tests in three-month intervals. Dr. Gawad explained, "as a first test, it will diagnose a heart attack quickly in those patients whose EKGs do not reveal clear evidence of one.


"The second test, the PIA-1 test, is a triage test for optimizing the performance of tPA, even though cardiac markers are not the indicators for administering tPA. Currently, the patient is diagnosed with a heart attack by means of the EKG and thereby becomes a candidate for tPA. The physician must decide whether the patient should be given tPA. Although the benefits of tPA are very clear, the failure rate is high. This new test is a treatment triage test.


"The third test product is the HFRS, which targets another group of patients -- those with heart failure. In 90% of heart failure cases, the patient had suffered a previous heart attack. This test paves the way toward the pre-selection of optimal treatment for heart failure patients, in contrast to the current trial and error approach.


"The logic behind these three tests is to diagnose those with no clear EKG evidence of heart attack, to triage those with clear evidence, and to assess biochemically the risk borne by those who have had a previous heart attack."


CardioGenics has also benefited from its agreement with Merck Chimie, S.A.S. concerning its paramagnetic beads utilized in the QLCA unit. Dr. Gawad said, "We approached all kinds of suppliers. Knowing that the product needed to be custom-built, we took the initiative to develop the beads in-house, and this was driven mainly by cost issues. We developed the beads and generated enough data to demonstrate their value. Merck Chimie, S.A.S. invited us to present our data at an international conference hosted by them, and we realized the commercial opportunity for the beads as a standalone product. We subsequently expanded on the data set and presented the data in 2007, which sparked the real interest." Merck Chimie, S.A.S. recently sent beads to CardioGenics for testing in preparation for commercial production.


About CardioGenics Holdings Inc.


Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.


Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.



Contact:
The Investor Relations Group
Investors: 212-825-3210
Adam S. Holdsworth

Public Relations: 212-825-3210
Laura Colontrelle





CardioGenics Holdings Inc.
CONTACT: Adam S. Holdsworth, The Investor Relations Group, Investors:
[phone]; or Laura Colontrelle, Public Relations: [phone]

[pontiyak]

CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
Ticker Symbol: U:CGNH





MISSISSAUGA, Ontario, Nov. 24 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. , a developer of technology and products targeting the immunoassay segment of the IVD testing market, reports that Merck Chimie S.A.S. ("Merck Chimie") is progressing to the next phase of the commercialization of CardioGenics' proprietary silver coated paramagnetic Beads ("Beads").


Per the agreement with Merck Chimie that was executed earlier this year, CardioGenics supplied Merck Chimie with its proprietary silver coated paramagnetic beads for polymer encapsulation by Merck Chimie using their proprietary polymer process. Merck Chimie has informed CardioGenics that its proprietary encapsulation of the Beads was successful and that they will start shipping the encapsulated Beads to CardioGenics for testing in December. CardioGenics intends to meet with Merck Chimie in early 2010 to examine the test results against Merck Chimie's predetermined quality specifications for the encapsulated Beads. Merck Chimie has also informed CardioGenics that, once the predetermined quality specifications for the encapsulated Beads are met, it will scale-up its production of the final encapsulated Beads to "commercial lots," in preparation for product launch. As part of the agreement, Merck Chimie will be responsible for all marketing and commercialization costs, with CardioGenics receiving 30% of the proceeds of sales.


Dr. Yahia Gawad, Chief Executive Officer, commented: "The implementation of our agreement with Merck Chimie is going smoothly, and we anticipate announcing a commercialization plan shortly after we review the test results early next year. Initiating commercialization of the Beads encapsulated by Merck Chimie will provide CardioGenics with a revenue stream that will strengthen our balance sheet."


"This is a significant development for our company and shareholders and we are encouraged to be working with Merck Chimie, the leading distributor of paramagnetic beads to the in vitro diagnostic market," concluded Dr. Gawad.


Magnetic Bead Fact Sheet and Market Opportunity

As presented in international meetings during 2008, CardioGenics' Beads represent a significant product advance, in terms of improving testing sensitivity for current laboratory testing platforms. Two white papers, one entitled "CGNH Magnetic Bead Fact Sheet" and another entitled "CGNH Magnetic Bead Market Opportunity" contain further details of the superiority of CardioGenics' Beads and their commercial potential, can be accessed and downloaded using the below links. CardioGenics' will also file a Current Report on Form 8-K regarding these developments.



To view and download the white papers, use the following links:

Cardiogenics Magnetic Beads Fact Sheet:

http://irgnews.com/node/1654


Magnetic Beads, The Needs and The Opportunity:

http://irgnews.com/node/1655


About CardioGenics Holdings Inc.


Through its CardioGenics subsidiaries, the Company develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. It has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada.


Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "Anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.






CardioGenics Holdings Inc.
CONTACT: The Investor Relations Group, Adam Holdsworth, [phone],
or Media Relations, Laura Colontrelle, [phone]

[pontiyak]

CardioGenics Holdings Inc. Featured in Medical Device Daily
Ticker Symbol: U:CGNH





MISSISSAUGA, Ontario, Nov. 13 /PRNewswire-FirstCall/ -- CardioGenics Holdings Inc. , a developer of technology and products targeting the immunoassay segment of the IVD testing market, was featured in Medical Device Daily's November 12, 2009 edition.


The article by Amanda Petersen, titled "CardioGenics aims to offer faster heart attack diagnosis," shares insights from CardioGenics CEO Yahia Gawad, MD regarding the company's point-of-care (POC) cardiac diagnostic technology. This technology includes the QL Care(R) Analyzer, designed to provide a more rapid diagnosis of heart attacks, to meet the guidelines established by the American Heart Association and the American College of Cardiology. It also includes the company's highly reflective paramagnetic beads, intended as a more light-sensitive alternative to beads currently used in 90% of medical lab analyzers.


The Medical Device Daily piece explains, "Speed of diagnosis is important when physicians are dealing with possible heart attack patients because they need to decide quickly how they are going to treat the patient, if they are going to be aggressive or use a more conservative therapy." In the article, Dr. Gawad notes, "For every hour you delay treating the patient it costs three lives, so the time is extremely important." Equally crucial, the article reports Gawad as saying, is the need to base that treatment decision on a sound diagnosis. The use of this POC test could reduce healthcare costs and offer faster diagnosis, Gawad states in the article.


The article goes on to describe the single-use cartridge QL Care(R) Analyzer, which CardioGenics states as offering a "quantum leap" in existing POC immunoassay technology: "In just six steps, the QL Care(R) Analyzer provides printed medical lab quality results in less than fifteen minutes." Gawad is reported in the article as noting that the company's initial target for the device is emergency rooms, chest pain clinics, and cardiac care units, but could be used in ambulances as well. CardioGenics is also reported as anticipating that the device cartridge can be ultimately adapted to run any number of immunoassay tests.


The article goes on to describe CardioGenics' other lead product, silver-coated magnetic beads that are more reflective and capable of delivering sensitivity five-to-ten times higher than competitive products in the chemiluminescence testing space.


The Medical Device Daily article is available online at http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=68998.



About CardioGenics Holdings Inc.


CardioGenics is dedicated to developing more sensitive diagnostic test products for the IVD market. CardioGenics has started several developmental processes aimed to achieve its objective "to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies." CardioGenics' operating philosophy is that "better diagnosis enhances the healthcare professionals' ability to provide better patient management which saves lives and reduces healthcare costs." Fulfilling unmet clinical testing needs is the driving force behind CardioGenics' innovations. Its current products include the QL Care Analyzer ("QLCA"), a state-of-the-art proprietary point of care ("POC") immunoanalyzer; a series of immunoassay tests to detect cardiac markers; and a proprietary method for improving the light collection from paramagnetic beads ("Beads"). You can learn more about CardioGenics at (cardiogenics.com).





CardioGenics Holdings Inc.
CONTACT: The Investor Relations Group: Investor Relations, Adam
Holdsworth, [phone], Or Public Relations: Laura Colontrelle,
[phone]

Web site: http://www.cardiogenics.com/

[di4]

JAG Media Holdings, Inc. Announces Definitive Share Purchase Agreement in Connection With Its Proposed Acquisition of CardioGenics Inc.
May 22, 2009 1:51:00 PM


Email Story Discuss on ZenoBank

View Additional ProfilesBOCA RATON, Fla., May 22 /PRNewswire-FirstCall/ -- JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) announced today that it and its newly created Canadian subsidiary, CardioGenics Exchangeco Inc., have entered into a definitive share purchase agreement with CardioGenics Inc. and its principle shareholder, Yahia Gawad pursuant to which Exchangeco will acquire all of the outstanding shares of CardioGenics Inc. in accordance with the terms of the share purchase agreement.


In consideration for the surrender of their CardioGenics common shares to Exchangeco, Exchangeco shall cause JAG Media to issue to the CardioGenics shareholders 422,183,610 shares of JAG Media common stock, par value $0.00001 (the "Share Consideration") in accordance with the terms of the share purchase agreement. The CardioGenics shareholders shall have the option to receive their pro-rata allocation of the Share Consideration in the form of (a) JAG Media common stock, to be issued at the closing (the "JAG Consideration Shares") or (b) exchangeable shares of Exchangeco, to be issued at the closing, which shares shall be exchangeable at any time after the closing into a number of shares of JAG Media common stock equal to such shareholders' pro rata allocation of the Share Consideration (the "Exchangeable Shares").


Upon issuance, the Share Consideration shall provide the CardioGenics shareholders with direct and/or indirect ownership of approximately 85% of JAG Media's outstanding common stock (on a fully diluted basis) as of the closing, assuming (for purposes of such calculation) that the Exchangeable Shares were fully exchanged for the permitted number of shares of JAG Media common stock immediately following the closing.


All JAG Consideration Shares received by any CardioGenics shareholders in exchange for their CardioGenics common shares shall not be registered for resale and, therefore, shall remain subject to the rights and restrictions of Rule 144. All Exchangeable Shares received by any CardioGenics shareholders in exchange for their CardioGenics common shares (and any JAG Media common stock into which such Exchangeable Shares may be exchanged) shall not be registered for resale prior to six (6) months following the closing and, therefore shall remain subject to the rights and restrictions of Rule 144 prior to any such registration.


At the closing, JAG Media's current directors will resign as directors of JAG Media and its subsidiaries and will also resign as officers and executives of JAG Media and its subsidiaries. JAG Media's board of directors will be replaced with designees of CardioGenics. The current directors of JAG Media will also enter into consulting agreements with the post-closing company at the closing, pursuant to which they will provide certain consulting services to assist the post-closing company in connection with certain transition matters.


The closing of the transaction is scheduled for June 30, 2009 and is subject to (a) the relevant parties to the transaction entering into a "Support Agreement" and "Exchange Rights Agreement," prior to the closing, enabling Exchangeco to fulfill its obligations with respect to the Exchangeable Shares; (b) CardioGenics closing on private placements of not less than $1,500,000; (c) CardioGenics delivering its audited financial statements to JAG Media in accordance with the share purchase agreement; (d) the CardioGenics shareholders and Debenture holders making certain deliveries, prior to the closing, as set forth in the share purchase agreement; and (e) the satisfaction of various customary conditions to closing. All parties are dedicating their full resources to execute the remaining matters for the closing.


A copy of the share purchase agreement will be filed by the Company on Form 8-K, which will be available on EDGAR.


About JAG Media Holdings, Inc.


JAG Media Holdings, Inc. is a provider of Internet-based equities research and financial information that offers its subscribers a variety of stock market research, news and analysis, including "JAG Notes", the Company's flagship early morning consolidated research product.


About CardioGenics Inc.


CardioGenics develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. CardioGenics has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development by CardioGenics, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, CardioGenics has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. CardioGenics' principal offices are located in Mississauga, Ontario, Canada.


SOURCE JAG Media Holdings, Inc.



----------------------------------------------
Stephen J. Schoepfer
President & COO of JAG Media Holdings
Inc.
[phone]
[e-mail]

[di4]

JAG Media Holdings, Inc. Announces Update of the Status of its Proposed Acquisition of CardioGenics Inc.
Apr 30, 2009 7:30:00 AM


Email Story Discuss on ZenoBank

View Additional ProfilesBOCA RATON, Fla., April 30 /PRNewswire-FirstCall/ -- JAG Media Holdings, Inc. (OTC Bulletin Board: JAGH) announced today an update of the status of its proposed acquisition of CardioGenics Inc. by a to-be-created Canadian subsidiary of JAG Media, for which the parties entered into a Letter of Intent on March 12, 2009. Currently, the parties are attending to various closing matters such as the preparation and negotiation of the required documents in connection with the acquisition, preparation of the required audited financial statements for CardioGenics and establishment of the two Canadian subsidiaries of JAG Media required in connection with the transaction. Both parties are dedicating their full resources to execute all the matters in preparation for closing. Based upon the current status of the various closing matters being attended to by the parties, the parties now project a closing date of May 29, 2009.


Notwithstanding the Letter of Intent, there is no assurance that the definitive documentation called for in the Letter of Intent will ever be executed, or if executed, that the proposed transaction between JAG Media and CardioGenics will be consummated. Further, to the extent that definitive agreements are reached, no assurances can be given that any such agreements will be entered into consistent with the current expectations of JAG Media and CardioGenics, as contemplated by the terms of the Letter of Intent.


About JAG Media Holdings, Inc.


JAG Media Holdings, Inc. is a provider of Internet-based equities research and financial information that offers its subscribers a variety of stock market research, news and analysis, including "JAG Notes", the Company's flagship early morning consolidated research product.


About CardioGenics Inc.


CardioGenics develops technology and products targeting the immunoassay segment of the In-Vitro Diagnostic testing market. CardioGenics has developed the QL Care Analyzer, a proprietary Point Of Care immuno-analyzer, which will run a number of diagnostic tests under development by CardioGenics, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, CardioGenics has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. CardioGenics' principal offices are located in Mississauga, Ontario, Canada.




SOURCE JAG Media Holdings, Inc.



----------------------------------------------
Stephen J. Schoepfer
President & COO
JAG Media Holdings
Inc.
[phone]
[e-mail]

[LGL8054]

Yorkville to Provide $5M Equity Line in Reverse Merger
Posted March 16, 2009 1:55PM PST
CardioGenics Inc., a Canadian medical product company, agreed to a reverse merger last week that will include a $5 million equity line from Yorkville Advisors.

CardioGenics will receive an 85% stake in the Florida shell company JAG Media Holdings, according to the March 12 letter of intent.

The merger is expected to close in late April after due diligence is completed, at least $1.5 million in financing has been secured, and other requirements have been met.

The company also agreed to a $5 million equity line with Jersey City, N.J.-based Yorkville. The equity line shares are to be issued over the course of 36 months, after they are registered.

JAG has been a financial and investment information company since 1989, but it has agreed on several occasions to reverse mergers with unrelated businesses.

In October, JAG signed a non-binding letter of intent to reverse merge with Colorado-based natural gas company BlueCreek Energy, but BlueCreek called off the discussions on Dec. 29. BlueCreek signed a letter of intent for an $80 million merger with the SPAC Dekania Corp. on the same day.

The merger ultimately unraveled last month after shareholders of Dekania refused to allow the SPAC more time to finalize the deal.

Yorkville is a senior secured lender to BlueCreek.

Shares of JAG closed at 22 cents on Friday, up almost 26% from the previous day.
Filing: 8-K

[antisubmarinewarfare]

[factfinder]

I really think all JAGH shareholders better start seriously thinking of teaming up together and I will lead the class action suit against Cryptometrics. Robert Barra used all of us JAGH shareholders behind the scenes so he could land a security deal based on a "potential merger". If you have ever seen the "Bourne Supremacy" what is about to happen to Barra might not be very different. Security only works if everone is on the same page! Our company JAGH would now be at least $50.00 to $350.00 per share but behind the legal documents he made "side deals" which is highly fraudulent and Illegal. JAGH legally owns Cryptometrics business because of this illegal operation. Click on the link below and you will understand why we are angry and justly so. And why we have a legal ground to take away his company!


http://www.thenational.ae/article/20080720/NATIONAL/784230457/1010&profile=1

[pontiyak]

test

[pontiyak]

Hi all.. I trust Cornell about as far as I could spit.....

that said.... anybody still short is about to get blown out of the water. Just based on what I'm hearing about contracts, and revenues, Crypto has significant strength on the basic fundamentals alone. With the majority of early shareholders holding JAGH in cert form, from Jag's early fight with shorty ( 2002 - 2006 ), to the very low O/S, and extremely low free tading shares..... I see a very explosive situation here.

Do your own DD please.

Good luck to all.

Cash is King.

IMHO

yak :)

[jonesieatl]

JAGH: 8-K out

JAGH is one of the rare companies whose stock price has stayed up handsomely in spite of YAGI dealings.

JAGH and YAGI just took care of a pesky 4.99% limitation I noted on another board recently.

http://www.sec.gov/Archives/edgar/data/1089029/000095012308001198/y48130e8vk.htm

"JAG Media and YA Global also agreed to increase the permitted maximum beneficial ownership of the Common Stock by YA Global upon exercise of the Warrants as set forth in the Warrants from 4.99% to 9.99% of the outstanding shares of Common Stock."

Various other YAGI-related activities with JAGH in that same 8-K

"Item 3.02 Unregistered Sales of Equity Securities

On January 31, 2008, JAG Media Holdings, Inc. (“Jag Media”) entered into a letter agreement (the “Letter Agreement”) with YA Global Investments, L.P., formerly Cornell Capital Partners, LP (“YA Global”),amending the terms and conditions of the previously disclosed Debentures, Warrants and other related documents between YA Global and Jag Media. Under the Letter Agreement, the parties acknowledged that $325,000.00 principal balance on the Debentures remained outstanding. YA Global agreed to promptly convert that outstanding Debenture balance and all accrued and unpaid interest aggregating $535,679 into restricted Jag Media Common Stock, par value $0.00001 per share (“Common Stock”) and to exercise on a cash basis a Warrant for 700,000 shares of Common Stock. On January 31, 2008, as a result of the conversion JAG Media issued 2,151,699 restricted shares of Common Stock and as a result of the exercise of the Warrants Jag Media issued 700,000 restricted shares of Common Stock and received $280,000 in cash. As a result of the conversion and termination of the Debentures, the restrictive covenants of the previously disclosed Securities Purchase Agreement, dated May 4, 2006, under which the Debentures and Warrants were issued, as well as the related Security Agreements, share reservation instructions, and Investor Registration Rights Agreements were terminated.
The parties also amended the remaining Warrants’ exercise price and exercise dates. The Warrants’ exercise price will be 88% of the average of the Volume Weighted Average Price of the Common Stock during the 30 trading days prior to their respective Exercise Restriction Dates. The Exercise Restriction Date, which is the date after which a Warrant may be exercised, shall be as follows:

1,300,000 shares 
 	  	30 trading days following the closing of the proposed merger between Jag Media and Cryptometrics, Inc. 
   
 	  	  
 2,000,000 shares 
 	  	March 31, 2008 
   
 	  	  
 2,000,000 shares 
 	  	June 30, 2008 
   
 	  	  
 3,000,000 shares 
 	  	September 30, 2008 
   
 	  	  
 3,000,000 shares 
 	  	December 31, 2008

This agreement amending the Warrants’ exercise price and their Exercise Restriction Dates terminates on February 27, 2008 if the closing of the merger with Cryptometrics has not yet occurred. "

[factfinder]

!!! The Golden King Rules !!!

[Dusty2]

factfinder, email me with what you have please. thanks

[factfinder]

You can't say you didn't have the chance.

[Dusty2]

Wow...read #10 table of contents about the risks. Seems both of these companies lose money and are printing presses. Now, with the merger, you have a larger company that still can't turn a profit. Just a bigger printing press is needed lol.

Beware folks.

[factfinder]

Merger is imminent. Keep your eyes open.

[BondGekko]

Can you give us supporting facts to support this notion. It sounds like you are saying this stock could reach 100 dollars a share. Please list the reasons why, thank you.

[factfinder]

Don't take my word for it but JAGH could be about to climb beyond the stratosphere. Simple mathematics can show that this could surpass everyones' wildest dreams. Even TASR could be shadowed in what you could be about to see. The entire investment world has been waiting for this one.

[factfinder]

Dusty check Pinksheets.com and look under filings and you will see it or SEC.gov.

[InYouWin]

JAG S4 Filing

http://app.quotemedia.com/quotetools/showFilingOutline.go?symbol=JGMHV&name=JAG MEDIA HOLDINGS INC: S-4&link=http%3A//quotemedia.10kwizard.com/contents.xml%3Fipage%3D5322690%26repo%3Dtenk

Read page 6 regarding closing date.

P.S. You'll have to copy and past the whole link.

[Dusty2]

I can't find info about the merger. Could someone please tell me about it?? Thanks

[CBGB]

sorry today was sad, JAGH doesn't even know how to do a r/m correctly. Almost a year now.

[BondGekko]

CBGB what are your share price predictions for JAGH, I hear people saying this thing could pull a TASR.

[orange6]

JAGH just a matter of time...PMGU just a matter of time

[CBGB]

JAGH getting a lot of volume S-4 out today merge date Dec 14th.
do dd

[CBGB]

Need to bring RB over here. em

[The Sweed]

that is very true, but thats a good thing Patrick Byrne(OSTK) is fighting the fight and what I heard in the past is hes also got a very strong guy who hates the naked short seliing and manipulation as well and he owns a company (BRK-A). Those are just a couple of guys I dont mind having on our side when it comes to it.

[pmunch]

Well, at 70 cents a share, it is not a cheap ticket to the show

If no merger and the rumors don't pan out ... it could be back at a quarter real quick, IMO

That is a big burden to tackle, a penny vs. NSS ?

[The Sweed]

yea that artical doesnt look the best, but as anyone who knows anything for sometime about whats going on in the naked short selling issues, will tell you that the big firms such as merril and UBSS, and morgan and their are so many others. Not only are they involved but the main individuals are the maket makers who make markets on all of the small cap stock(otcbb or pink sheets), soo it was noted some time ago in an artical that over 5000 small stocks have either been taken to below pennies or even completely destroyed. Just imagine the amount of funds that individuals have lost over the years b/c of this naked short selling. the number is soo large that many companys couldnt handle it, possibly not even the whole market. So ill back anyone who will fights these guys, and yes the CEO of Overstock may sound alot like bs to some people but there had to be a point proven and he stepped up. yes, every firm will try to knock anyone they can to stop this from happening, and of course they knock penny stock guys b/c there the ones that reconize this the most when helping a small company. I guess will see if this merger goes through and see what kind of short squeeze or how many people have been short this stock when it happens. It kinda seems time for them to stop this and to be taught a lesson.

[pmunch]

I don't like this article ... Any comments ?

http://portland.indymedia.org/en/2007/02/354430.shtml